TherapeuticsMD (NASDAQ:TXMD) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of TherapeuticsMD (NASDAQ:TXMD) in a report issued on Friday. The brokerage set a “hold” rating on the stock.

TherapeuticsMD Price Performance

Shares of TherapeuticsMD stock opened at $1.09 on Friday. The company’s fifty day simple moving average is $1.38 and its two-hundred day simple moving average is $1.62. TherapeuticsMD has a 12-month low of $1.05 and a 12-month high of $2.75.

Hedge Funds Weigh In On TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP raised its stake in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 18.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 636,622 shares of the company’s stock after acquiring an additional 101,282 shares during the period. Clearline Capital LP owned approximately 5.52% of TherapeuticsMD worth $1,025,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.